IQVIA Holdings Inc. (NYSE:IQV) Short Interest Update

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) saw a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 2,810,000 shares, a decrease of 9.6% from the November 30th total of 3,110,000 shares. Currently, 1.6% of the shares of the company are short sold. Based on an average daily trading volume, of 1,520,000 shares, the days-to-cover ratio is currently 1.8 days.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in IQV. First Foundation Advisors increased its position in IQVIA by 3.8% during the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company's stock worth $245,000 after purchasing an additional 43 shares during the last quarter. Invera Wealth Advisors LLC raised its position in shares of IQVIA by 0.3% in the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company's stock worth $3,183,000 after buying an additional 46 shares during the period. Private Trust Co. NA boosted its holdings in IQVIA by 10.7% in the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock valued at $115,000 after acquiring an additional 47 shares during the last quarter. Oregon Public Employees Retirement Fund grew its position in IQVIA by 0.3% during the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company's stock valued at $3,313,000 after acquiring an additional 48 shares during the period. Finally, Clear Harbor Asset Management LLC raised its holdings in shares of IQVIA by 1.3% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company's stock worth $941,000 after purchasing an additional 50 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on IQV shares. StockNews.com downgraded IQVIA from a "buy" rating to a "hold" rating in a research note on Thursday, November 28th. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a report on Wednesday, December 11th. The Goldman Sachs Group lowered their price target on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Stephens started coverage on shares of IQVIA in a research note on Friday, December 20th. They issued an "overweight" rating and a $250.00 price objective for the company. Finally, TD Cowen lowered their target price on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $255.82.

IQVIA Trading Down 0.5 %

Shares of NYSE IQV traded down $0.94 during midday trading on Wednesday, reaching $196.51. 718,908 shares of the stock were exchanged, compared to its average volume of 1,193,056. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market capitalization of $35.67 billion, a P/E ratio of 25.79, a P/E/G ratio of 2.05 and a beta of 1.49. The stock has a 50 day moving average price of $203.54 and a 200-day moving average price of $222.31. IQVIA has a 52-week low of $187.62 and a 52-week high of $261.73.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.